Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

American Airlines reported for 6 months of 2023

7/20/23 AAL

The Johnson & Johnson announced a quarterly dividend

7/20/23 JNJ

The BlackRock announced a quarterly dividend

7/20/23 BLK

Johnson & Johnson reported for 6 months of 2023

7/20/23 JNJ

Seligdar increased gold sales by 2.3 times in the first half of the year

7/20/23 SELG

PIK became a co-investor in three residential projects of Sense developer in Moscow

7/20/23 PIKK

The Nokia announced a quarterly dividend

7/20/23 NOK

Samolet Plus invested in the aggregator of new buildings Dombook

7/20/23 SMLT

The Bank of America announced a quarterly dividend

7/20/23 BAC

TSMC reported for 6 months of 2023

7/20/23 TSM